Table 1.
SiNPs | isotope | half-life | labeling strategy | application | ref |
---|---|---|---|---|---|
C dots | 124I | 4.2 days | chelator-based | molecular imaging | 8, 30 |
C' dots | 89Zr | 78.4 h | chelator-based/chelator-free | molecular imaging | 18 |
dSiO2 | 64Cu | 12.7 h | chelator-based | imaging of LN metastasis | 11 |
dSiO2 | 89Zr or 68Ga | 78.4 h or 67.7 min | chelator-free | biodistribution/LN imaging | 14 |
dSiO2 | 64Cu | 12.7 h | chelator-free | LN imaging | 13 |
MSN | 18F | 109.8 min | in vivo labeling | tumor imaging | 23 |
MSN | *As | 72As, 26 h | chelator-free | biodistribution | 31 |
MSN | 45Ti | 3.08 h | chelator-free | tumor imaging | 32 |
MSN | 64Cu | 12.7 h | chelator-based | molecular imaging/drug delivery | 9 |
MSN | 89Zr | 78.4 h | chelator-free | biodistribution | 12 |
HMSN | 64Cu | 12.7 h | chelator-based | molecular imaging/drug delivery | 28 |
HMSN | 89Zr | 78.4 h | chelator-free | theranostics | 25 |
Note: C dots, Cornell dots; C' dots, Cornell prime dots; dSiO2, dense silica nanoparticles; MSN, mesoporous silica nanoparticles; HMSN, hollow mesoporous silica nanoparticles; LN, lymph node. Molecular imaging, tumor diagnosis based on actively targeted imaging; tumor imaging, tumor diagnosis based on the EPR effect.